Journal of Clinical & Translational Endocrinology · 2016 · 24 citations · 35 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyDiabetologyDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyLipid ManagementLipid-lowering TherapyControl Group DesignLdl Cholesterol LoweringLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionMatched Control GroupParallel Study DesignsPlasma Cholesterol LevelsSurrogate Endpoints
AIMS: This preliminary randomized, parallel-group comparative study evaluated the efficacy of ipragliflozin for reduction of small dense low-density lipoprotein cholesterol (sd LDL-C) levels in Japanese patients with type 2 diabetes mellitus (T2DM). METHODS: system; the secondary endpoints included changes in the sd LDL-C/large buoyant LDL-C (lb LDL-C) ratio, a surrogate marker for LDL particle size, and percent changes in routine lipid parameters. RESULTS: = 0.006) as independent factors contributing to the reduction in sd LDL-C. CONCLUSIONS: Ipragliflozin may have a potential for lowering sd LDL-C levels associated with increasing LDL particle size in Japanese patients with T2DM.
35
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo, Enyu Imai, Masaru Horio et al. · American Journal of Kidney Diseases · 2009 · 6.4K citations